Recent Transactions

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment 

Advised CME Group, Inc., the operator of a leading global derivatives marketplace, on the structured sale of its 25% equity stake in Bursa Malaysia Derivatives Berhad to Bursa Malaysia Berhad

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company   

Advised Nippon Television Holdings, a media and content company engaged in production and broadcasting primarily in Japan, on the acquisition of Tipness Limited, the fourth largest fitness club company in Japan,  from Suntory Holdings and Marubeni Corporation

Advised Dentsu Inc., Asia’s largest advertising agency, on the sale of its retail data analytics subsidiary Aztec, to IRI, a global market research company

Advised Village Roadshow Entertainment Group on its $275 million mezzanine and equity capital raise from a group of investors

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement